To date, several in vivo studies have shown the effectiveness of VISTA-targeted drugs in combination with PD-1/PD-L1 or CTLA-4 inhibitors, although their effectiveness varies among drug combinations and cancer types.16 This evidence concerns the gene PDCD1 and cancer.